Alumis Inc. focuses on TYK2 inhibitors ESK-001 and A-005, with ESK-001 in Phase 3 for plaque psoriasis. Find out why ALMS ...

Alumis and Acelyrin have filed a definitive proxy statement/prospectus with the US Securities and Exchange Commission for the proposed merger of the companies.

Potential Alumis Inc. (NASDAQ:ALMS) shareholders may wish to note that the Independent Director, Alan Colowick, recently bought US$130k worth of stock, paying US$7.04 for each share. Although the ...

Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheetBoards unanimously recommend stockholders ...

Alumis announced that it entered into a licensing and collaboration agreement with Kaken. Alumis is licensing ESK-001, a drug aimed at treating immune dysregulation in various diseases ...

SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision ...

A potential buyer threatened to upend Alumis Inc.'s merger deal with Acelyrin Inc. as late as Monday, according to a Securities and Exchange Commission filings Thursday detailing the merger.